- Chardan has initiated coverage on Oncorus Inc (NASDAQ:ONCR) with a Buy rating and a price target of $5.
- The analysts based it on the company's commercial potential with its lead oncolytic virus immunotherapy ONCR-177 from its HSV platform.
- Oncorus' HSV platform utilizes the herpes simplex virus (HSV) type 1 backbone that incorporates more transgenes, retains the ability to replicate in tumor cells, and has orthogonal safety strategies to attenuate viral replication in healthy tissues.
- Related: Why Did Oncorus Shares Slump To 52-Week Low Today?
- The company's lead program, ONCR-177, is being evaluated as a monotherapy and combined with Merck & Co Inc's (NYSE:MRK) Keytruda in an ongoing phase I study for solid tumors.
- Chardan notes that treatment in the monotherapy arm was "well tolerated with no dose-limiting toxicities," and the recommended phase 2 dose was determined as 4e8 PFU/dose in 4 mL.
- The analyst projects an initial product launch for the program in 2026. Using a probability of success of 25% for the program, Chardan estimates ONCR-177 netting ~$230 million in probability-adjusted global sales in 2030.
- Price Action: ONCR shares are down 3.40% at $1.57 during the market session on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Chardan Sees Over 200% Upside On This Small-Cap Cancer-Focused Stock
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks